PHiD-CV induces anti-Protein D antibodies but does not augment pulmonary clearance of nontypeable Haemophilus influenzae in mice

Autor: John S. Tregoning, Yanwen Li, Paul R. Langford, Matthew K. Siggins, Shamez N Ladhani, Simren K. Gill
Přispěvatelé: SPort Aiding medical Research for KidS (SPARKS)
Rok vydání: 2014
Předmět:
D CONJUGATE VACCINE
Chronic bronchitis
Neutrophils
Respiratory System
CHILDREN
Research & Experimental Medicine
medicine.disease_cause
Pneumococcal conjugate vaccine
DISEASE
Haemophilus influenzae
Pneumococcal Vaccines
Innate immunity
Mice
Inbred BALB C
biology
Respiratory tract infections
11 Medical And Health Sciences
OTITIS-MEDIA
Antibodies
Bacterial
Co-infection
Infectious Diseases
CHRONIC-BRONCHITIS
Medicine
Research & Experimental
Superinfection
Molecular Medicine
VIRUS
Female
Antibody
Nontypeable Haemophilus influenzae
Life Sciences & Biomedicine
medicine.drug
Haemophilus Infections
Lipoproteins
Immunology
Virus
Microbiology
Bacterial Proteins
Orthomyxoviridae Infections
Virology
otorhinolaryngologic diseases
medicine
Pneumonia
Bacterial
Animals
INNATE IMMUNE-RESPONSES
SIALIC-ACID
Science & Technology
General Veterinary
General Immunology and Microbiology
business.industry
Body Weight
Public Health
Environmental and Occupational Health
COMMUNITY-ACQUIRED PNEUMONIA
Pneumonia
Immunoglobulin D
06 Biological Sciences
Influenza
Disease Models
Animal
Immunization
biology.protein
07 Agricultural And Veterinary Sciences
business
Carrier Proteins
LUNG
Zdroj: Vaccine. 33(38)
ISSN: 1873-2518
Popis: Background A recently-licensed 10-valent pneumococcal conjugate vaccine (PHiD-CV; Synflorix, GSK) uses Protein D from Haemophilus influenzae as a carrier protein. PHiD-CV therefore has the potential to provide additional protection against nontypeable H. influenzae (NTHi). NTHi frequently causes respiratory tract infections and is associated with significant morbidity and mortality worldwide and there is currently no vaccine. Methods We developed mouse models of NTHi infection and influenza/NTHi superinfection. Mice were immunized with PHiD-CV, heat-killed NTHi, or a 13-valent pneumococcal conjugate vaccine that did not contain Protein D (PCV13; Prevenar, Pfizer) and then infected intranasally with NTHi. Results Infection with NTHi resulted in weight loss, inflammation and airway neutrophilia. In a superinfection model, prior infection with pandemic H1N1 influenza virus (strain A/England/195/2009) augmented NTHi infection severity, even with a lower bacterial challenge dose. Immunization with PHiD-CV produced high levels of antibodies that were specific against Protein D, but not heat-killed NTHi. Immunization with PHiD-CV led to a slight reduction in bacterial load, but no change in disease outcome. Conclusions PHiD-CV induced high levels of Protein D-specific antibodies, but did not augment pulmonary clearance of NTHi. We found no evidence to suggest that PHiD-CV will offer added benefit by preventing NTHi lung infection.
Databáze: OpenAIRE
Externí odkaz: